United States Neurological Diagnostic and Monitoring Equipment Market Outlook to 2033 – Electrical Activity Testing and ICP Monitoring Devices

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$4995
Buy Report

Published: February 20, 2026 Report Code: GDME47219CCDB-ST

Select Item

GlobalData’s “United States Neurological Diagnostic and Monitoring Equipment Outlook to 2033” is a comprehensive databook report, covering key market data on the United States Neurological Diagnostic and Monitoring Equipment market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Electrical Activity Testing and ICP Monitoring Devices

The United States Neurological Diagnostic and Monitoring Equipment Market report provides key information and data on –
• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
• 2025 company share data for Neurological Diagnostic and Monitoring Equipment Market.
• Global corporate-level profiles of key companies operating within the United States Neurological Diagnostic and Monitoring Equipment Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

United States Neurological Diagnostic and Monitoring Equipment is segmented as follows:_x000D_

• Electrical Activity Testing_x000D_

• ICP Monitoring Devices

Reasons to Buy

The United States Neurological Diagnostic and Monitoring Equipment Market report helps you to develop:

• Business strategies by identifying the key market segments poised for strong growth in the future.

• Market-entry and market expansion strategies.

• Design competition strategies by identifying who-stands-where in the market.

• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

Natus Medical Inc
Nihon Kohden Corp
Medtronic Plc
Masimo Corp
Cadwell Industries Inc
Integra LifeSciences Corp
Compumedics Ltd
Megin Oy
ANT Neuro BV

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 What Is This Report About?

2.2 Neurological Diagnostic and Monitoring Equipment Devices Market Segmentation

2.3 Definitions of Markets Covered in the Report

3 Neurological Diagnostic and Monitoring Equipment Market, United States

3.1 Neurological Diagnostic and Monitoring Equipment Market, United States, Revenue ($m), 2018-2033

3.1.1 Electrical Activity Testing Market, United States, Revenue ($m), by Segment, 2018-2033

3.1.2 ICP Monitoring Devices Market, United States, Revenue ($m), by Segment, 2018-2033

3.2 Neurological Diagnostic and Monitoring Equipment Market, United States, Volume (Units), 2018-2033

3.2.1 Electrical Activity Testing Market, United States, Volume (Units), by Segment, 2018-2033

3.2.2 ICP Monitoring Devices Market, United States, Volume (Units), by Segment, 2018-2033

3.3 Neurological Diagnostic and Monitoring Equipment Market, United States, Average Price ($), 2018-2033

3.4 Neurological Diagnostic and Monitoring Equipment Market, United States, Company Share by Revenue ($m), 2025

4 Overview of Key Companies in United States, Neurological Diagnostic and Monitoring Equipment Market

4.1 Natus Medical Inc

4.1.1 Company Overview

4.2 Nihon Kohden Corp

4.2.1 Company Overview

4.3 Medtronic Plc

4.3.1 Company Overview

4.4 Masimo Corp

4.4.1 Company Overview

4.5 Cadwell Industries Inc

4.5.1 Company Overview

4.6 Integra LifeSciences Corp

4.6.1 Company Overview

4.7 Compumedics Ltd

4.7.1 Company Overview

4.8 Megin Oy

4.8.1 Company Overview

4.9 ANT Neuro BV

4.9.1 Company Overview

5 Neurological Diagnostic and Monitoring Equipment Market Pipeline Products

6 Recent Developments

6.1 Corporate Communications

6.1.1 Jan 08, 2026: Natus Sensory Appoints Arne Boye Nielsen to Board of Directors

6.1.2 Nov 21, 2025: Stroke Prevention Study CREST-2 Stenting

6.1.3 Nov 20, 2025: PhotoPharmics Exceeds Enrollment Goal with 350 Participants in Remote Phase 3 Clinical Trial for Parkinson’s Disease

6.1.4 Nov 19, 2025: Renowned Neuromuscular Expert to Lead New NYU Langone ALS Center

6.1.5 Nov 05, 2025: Genesys Strike Negotiations Update

6.1.6 Nov 05, 2025: W&L Expands Parental Leave Benefits for Faculty and Staff

6.1.7 Nov 04, 2025: BrainScope Appoints Matt Adams as Chief Executive Officer

6.1.8 Oct 30, 2025: End Brain Cancer Initiative Partners with Exvade Bioscience to Raise Awareness of Brain Cancer Study

6.1.9 Oct 30, 2025: Siddiqui Performs World’s First Robotic Microsurgical Intracranial Brain Surgery

6.1.10 Oct 24, 2025: Payman Khales Becomes Integer President and CEO

6.1.11 Oct 21, 2025: Laura Jane Ramsburg Appointed Director of Staniar Gallery

6.1.12 Oct 17, 2025: W&L Welcomes New Trustees Thomas J. Sheehan and Andrew W. Tate

6.1.13 Oct 07, 2025: Altoida Expands Advisory Board with Global Leaders in AI, Pharma, and Alzheimer’s Advocacy

6.1.14 Oct 01, 2025: College of Nursing and Public Health Advisory Board Welcomes Marc Adler and Jennifer McIntosh

6.1.15 Sep 24, 2025: CWSL Alumna Sherry S. Bahrambeygui Elected to UC San Diego Foundation Board

6.1.16 Sep 12, 2025: Christina J. Yang, MD, Joins Hassenfeld Children’s Hospital as Chief of Pediatric Otolaryngology

6.1.17 Sep 12, 2025: Renowned Specialist to Lead New Dry Eye Service at NYU Langone Eye Center

6.1.18 Sep 08, 2025: UC San Diego Foundation Announces New Trustees

6.1.19 May 16, 2025: Magstim Granted EU MDR Certification

6.2 Financial Announcements

6.2.1 Sep 25, 2025: Integer Announces Conference Call to Discuss Third Quarter 2025 Results

6.2.2 May 05, 2025: Integra LifeSciences Reports First Quarter 2025 Financial Results

6.2.3 Apr 18, 2025: Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025

6.2.4 Apr 17, 2025: GE HealthCare to Announce First Quarter 2025 Results on April 30, 2025

6.2.5 Feb 04, 2025: Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on February 25, 2025

6.3 Government and Public Interest

6.3.1 Dec 01, 2025: Integra LifeSciences Leadership to Present at Citi 2025 Global Healthcare Conference

6.3.2 Nov 17, 2025: GE HealthCare Management to Present at Upcoming Investor Conference

6.3.3 Oct 29, 2025: Seer to Participate in Upcoming November Investor Conferences

6.3.4 Sep 25, 2025: Integer Announces Conference Call to Discuss Third Quarter 2025 Results

6.3.5 Sep 24, 2025: Eysz Announces Positive Results of NIH-Funded Study on Novel Absence Seizure Screening Tool

6.3.6 Aug 29, 2025: Integra LifeSciences Leadership to Present at Wells Fargo and Morgan Stanley Healthcare Investor Conferences

6.3.7 Aug 21, 2025: GE HealthCare Management to Present at Upcoming Investor Conferences

6.3.8 Aug 12, 2025: Integer to Present at 2025 Wells Fargo Healthcare Conference on Sept. 4

6.3.9 Feb 10, 2025: GE Healthcare Management to Present at Upcoming Investor Conference

6.4 Other Significant Developments

6.4.1 Nov 24, 2025: NeuroPace Announces Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

6.4.2 Nov 10, 2025: Hope Therapeutics, Inc. Announces First-in-Florida Initiation of One Day Depression Treatment

6.4.3 Oct 24, 2025: Laser Procedure Offers Solutions For Epilepsy And Brain Tumors

6.4.4 Jun 02, 2025: Listening to Lives Behind the Numbers: Linus Health Study Champions Person-Centered Brain Health Assessments

6.5 Product News

6.5.1 Jan 14, 2026: Integer to Showcase Innovations in Neuromodulation, Miniaturized Active Implantable Device Technology During NANS 2026 Annual Meeting

6.5.2 Nov 26, 2025: Neuro Event Labs Receives FDA 510(k) Clearance for Nelli Seizure Monitoring System

6.5.3 Nov 20, 2025: PhotoPharmics Exceeds Enrollment Goal with 350 Participants in Remote Phase 3 Clinical Trial for Parkinson’s Disease

6.5.4 Nov 18, 2025: QuantalX Receives FDA De Novo Clearance for Delphi-MD

6.5.5 Nov 15, 2025: Evidence Builds for Disrupted Mitochondria as Cause of Parkinson’s

6.5.6 Nov 10, 2025: URI Team Develops Tabletop Device to Study Long-Term Effects of Traumatic Brain Injury

6.5.7 Nov 05, 2025: MMI Receives IDE Approval from FDA for First Robotic Microsurgical Study in Alzheimer’s Patients

6.5.8 Oct 30, 2025: Siddiqui Performs World’s First Robotic Microsurgical Intracranial Brain Surgery

6.5.9 Oct 29, 2025: FDA-Approved Focused Ultrasound Treatment for Essential Tremor Now Used for Parkinson's

6.5.10 Oct 21, 2025: Nexalin’s DIFS Neurostimulation Demonstrates Cognitive Improvements in Alzheimer’s and Dementia

6.5.11 Oct 20, 2025: Neupulse Partnership Introduces Innovative Wearable for Tourette Syndrome

6.5.12 Oct 15, 2025: XRHealth Receives U.S. Patent for Advanced XR System Measuring Upper-Limb Impairments

6.5.13 Oct 07, 2025: Brain Stimulation May Reduce Cannabis Addiction in People with Multiple Sclerosis

6.5.14 Sep 24, 2025: Eysz Announces Positive Results of NIH-Funded Study on Novel Absence Seizure Screening Tool

6.5.15 Sep 23, 2025: FDA Clears Cionic Neural Sleeve 2 For Enhanced Mobility Care

6.5.16 Jul 28, 2025: Anywhere powered by Linus Health Expands Equitable Access to Early Detection of Cognitive Impairment

6.5.17 Mar 18, 2025: Anywhere for Health Systems Delivers Clinical-Grade Cognitive Assessments Remotely

7 Appendix

7.1 Research Methodology

7.1.1 Coverage

7.1.2 Secondary Research

7.1.3 Primary Research

7.1.4 Market Modeling and Forecasting

7.1.5 Company Share Analysis

7.1.6 Benchmarking

7.2 GlobalData Consulting

7.3 Contact Us

7.4 Disclaimer

Table

Table 1: Neurological Diagnostic and Monitoring Equipment Market, United States, Revenue ($m), USD Constant, 2018-2033

Table 2: Electrical Activity Testing Market, United States, Revenue ($m), USD Constant, 2018-2033

Table 3: ICP Monitoring Devices Market, United States, Revenue ($m), USD Constant, 2018-2033

Table 4: Neurological Diagnostic and Monitoring Equipment Market, United States, Volume (Units), 2018-2033

Table 5: Electrical Activity Testing Market, United States, Volume (Units), 2018-2033

Table 6: ICP Monitoring Devices Market, United States, Volume (Units), 2018-2033

Table 7: Neurological Diagnostic and Monitoring Equipment Market, United States, Average Price ($), 2018-2033

Table 8: Neurological Diagnostic and Monitoring Equipment Market, United States, Company Share by Revenue ($m), 2025

Table 9: Neurological Diagnostic and Monitoring Equipment Market Pipeline Products

Table 10: Total Number of Primary Research Participants, Neurology Devices Market, by Country

Figures

Figure 1: Neurological Diagnostic and Monitoring Equipment Market, United States, Revenue ($m), USD Constant, 2018-2033

Figure 2: Electrical Activity Testing Market, United States, Revenue ($m), USD Constant, 2018-2033

Figure 3: ICP Monitoring Devices Market, United States, Revenue ($m), USD Constant, 2018-2033

Figure 4: Neurological Diagnostic and Monitoring Equipment Market, United States, Volume (Units), 2018-2033

Figure 5: Electrical Activity Testing Market, United States, Volume (Units), 2018-2033

Figure 6: ICP Monitoring Devices Market, United States, Volume (Units), 2018-2033

Figure 7: Neurological Diagnostic and Monitoring Equipment Market, United States, Company Share (%), 2025

United States Neurological Diagnostic and Monitoring Equipment Market Outlook to 2033 – Electrical Activity Testing and ICP Monitoring Devices standard reports
Currency USD
$4,995

Can be used by individual purchaser only

Most Popular
$9,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$14,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Neurology Devices reports
Medical Devices
New
Adult Feeding Tubes and Formula Market Size by Segments, Share,…
$7,500 | October 2026
Medical Devices
New
Neurovascular Thrombectomy Devices Market Size by Segments, Share, Regulatory, Reimbursement,…
$7,500 | October 2026
Medical Devices
New
Body Contouring Devices Market Size by Segments, Share, Regulatory, Reimbursement,…
$7,500 | October 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at United States Neurological Diagnostic and Monitoring Equipment Market Outlook to 2033 – Electrical Activity Testing and ICP Monitoring Devices in real time.

  • Access a live United States Neurological Diagnostic and Monitoring Equipment Market Outlook to 2033 – Electrical Activity Testing and ICP Monitoring Devices dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more